NASDAQ:XBIT - Nasdaq - CA98400H1029 - Common Stock - Currency: USD
NASDAQ:XBIT (2/24/2025, 12:12:04 PM)
3.01
+0.02 (+0.67%)
The current stock price of XBIT is 3.01 USD. In the past month the price decreased by -19.19%. In the past year, price decreased by -53.64%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.23 | 361.77B | ||
AMGN | AMGEN INC | 15.64 | 166.47B | ||
GILD | GILEAD SCIENCES INC | 24.11 | 138.48B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1666.66 | 124.17B | ||
REGN | REGENERON PHARMACEUTICALS | 15.68 | 78.21B | ||
ARGX | ARGENX SE - ADR | N/A | 38.32B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.18B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.25B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.43B | ||
NTRA | NATERA INC | N/A | 21.16B | ||
BIIB | BIOGEN INC | 8.57 | 20.58B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.89 | 16.15B |
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 92 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
XBIOTECH INC
5217 Winnebago Lane
Austin TEXAS 78744 US
CEO: John Simard
Employees: 94
Company Website: http://www.xbiotech.com/
Investor Relations: https://investors.xbiotech.com
Phone: 15123862900
The current stock price of XBIT is 3.01 USD. The price increased by 0.67% in the last trading session.
The exchange symbol of XBIOTECH INC is XBIT and it is listed on the Nasdaq exchange.
XBIT stock is listed on the Nasdaq exchange.
XBIOTECH INC (XBIT) has a market capitalization of 91.74M USD. This makes XBIT a Micro Cap stock.
XBIOTECH INC (XBIT) currently has 94 employees.
XBIOTECH INC (XBIT) has a resistance level at 6.95. Check the full technical report for a detailed analysis of XBIT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XBIT does not pay a dividend.
XBIOTECH INC (XBIT) will report earnings on 2025-03-13.
XBIOTECH INC (XBIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).
The outstanding short interest for XBIOTECH INC (XBIT) is 4.59% of its float. Check the ownership tab for more information on the XBIT short interest.
ChartMill assigns a fundamental rating of 2 / 10 to XBIT. XBIT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months XBIT reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS decreased by -20.82% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -16.24% | ||
ROE | -17.8% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 83% to XBIT. The Buy consensus is the average rating of analysts ratings from 7 analysts.